Naslov
Challenges of technology transfer in the vaccine development process

Autori
Kovač, Ivana ; Maslać, Vlado ; Horvatinović, Tin

Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), znanstveni

Izvornik
80th International Scientific Conference on Economic and Social Development and 10th International OFEL Conference "Diversity, Equity and Inclusion: The Essence of Organisational Well-Being" Economic and Social Development - Book of proceedings / Tipurić, Darko ; Krajnović, Ana ; Recker, Nicholas - Varaždin : Zagreb : Varazdin Development and Entrepreneurship Agency ; University North ; CIRU ; University of Dubrovnik, 2022, 424-434

Skup
80th International Scientific Conference on Economic and Social Development and 10th International OFEL Conference: Diversity, Equity and Inclusion: The Essence of Organisational Well-Being

Mjesto i datum
Dubrovnik, Hrvatska, 01.04.2022. - 02.04.2022

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
technology transfer ; vaccines ; COVID-19 ; end of the pandemic

Sažetak
Technology transfer accelerates successful adoption of innovations. In doing so, it seeks to make the knowledge and technology developed in its public laboratories available to public and private entities in a variety of ways. Technology transfer is a key factor that strongly influences economic growth, both short-term and long-term. Structural changes to the entire economy are almost impossible without effective technology transfer and a well-defined innovation system of the country. The transfer of vaccine technology can have a huge impact on vaccine access and subsequent health improvements. Although vaccines against COVID-19 have developed rapidly, all steps have been taken to ensure their safety and efficacy. It can be concluded that vaccines against COVID-19 were rapidly developed and distributed to help combat the pandemic. The following COVID-19 vaccines are currently approved in the European Union, including the Republic of Croatia - Comirnatym (Australia), Spikevax (Spain), Vaxzevria (UK) and COVID-19 Vaccine Janssen (Belgium). It can be concluded that in all countries producing vaccines for COVID-19 there has been an increase in gross domestic product which can be linked to the interest of countries in procuring the appropriate vaccine to finally bring the pandemic to an end.

Izvorni jezik
Engleski

Znanstvena područja
Ekonomija

POVEZANOST RADA